Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Clinical evidence

ESK-001-022

12 evidence topics · 2 sources

Objective
Location and study date
Recruitment and results status in the ClinicalTrials.gov record
FieldQuoted record
Overall status“Completed”
Results“No Results Posted”
Last update posted“2026-05-12”
Study design
Eligibility criteria
Key inclusion and exclusion criteria in the ClinicalTrials.gov record
CriterionQuoted record
Inclusion, all participants“Body mass index between 18.0 and 40.0 kg/m2”
Inclusion, hepatic impairment“Diagnosis of chronic (> 6 months), stable hepatic impairment with no clinically significant changes within 30 days prior to dosing, as determined by medical history”
Exclusion, all participants“Uncontrolled treated/untreated hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 105 mmHg), or uncontrolled treated/untreated hypotension (systolic blood pressure < 90 mmHg and/or diastolic blood pressure < 50 mmHg), or resting pulse rate < 45 or > 100 bpm.”
Exclusion, healthy volunteers“Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator or designee.”
Exclusion, healthy volunteers“Positive hepatitis panel and/or positive human immunodeficiency virus test.”
Exclusion, hepatic impairment“History of any uncontrolled or unstable renal, hematological, gastrointestinal, neurological, endocrine, or psychiatric disorder, as determined by the investigator or designee, within 6 months prior to screening.”
Exclusion, hepatic impairment“History or current diagnosis of uncontrolled or significant cardiac disease indicative of a significant risk of safety for participation in the study.”
Exclusion, hepatic impairment“Liver function tests outside the appropriate reference ranges that are not consistent with hepatic dysfunction, as determined by the investigator or designee.”
Exclusion, hepatic impairment“QTcF > 480 ms for males or > 490 ms for females at screening or check-in, as confirmed from the mean of the original value and 2 repeats.”
Ages eligible for study“18 Years to 75 Years (Adult, Older Adult )”
Sexes eligible for study“All”
Accepts healthy volunteers“Yes”
Treatment
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary
  • The hepatic impairment study has no posted results, and the report holds no published results; its ClinicalTrials.gov record reads “No Results Posted”.
  • The design is open-label and non-randomized, with one dose of ESK-001 of unstated strength and a 48-hour outcome time frame.
  • Actual enrollment was 32 participants, against 48 estimated at registration and a planned structure of up to 24 healthy volunteers and 8 participants each with mild, moderate, and severe hepatic impairment; the number enrolled in each group is not reported.